Today, the US NIH awarded Pataigin a research grant to further development of Pataigin’s Rigel antimicrobial susceptibility test.
“We thank the NIH for supporting this research,” said Pataigin CEO Erik Nilsson. “Rigel promises to reduce medical costs while saving lives now lost to infectious disease.”
The grant, entitled Isotopic Labeling Rapid Antimicrobial Susceptibility Testing, furthers development of the rapid and sensitive Rigel AST test using lipid microbiology technology. Rigel can determine appropriate antibiotic therapy in six hours, compared to days for conventional tests.
“Rigel is based on my lab’s longstanding research into lipid microbiology,” said Prof. Robert Ernst, the Dr. Paul and Mrs. Jean Corcoran Professor and Vice-Chair, Department of Microbial Pathogenesis, School of Dentistry, University of Maryland, Baltimore. “In this research, we extend lipid microbiology beyond microbial ID to antimicrobial susceptibility testing.” Prof. Ernst is a collaborator on the grant.
Bacteremia and sepsis remain major health problems with high mortality. Progression is often rapid, so that a single hour saved in diagnosis time can significantly reduce septicemia death rates. Faster tests are therefore needed to save lives. By significantly accelerating test results, Rigel offers the potential of improved clinical outcomes at lower cost to hospitals. Furthermore, Rigel is fast enough to allow better antimicrobial stewardship approaches to be used in place of empiric treatment.
The grant has award number R43AI162525 from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and is made under the Small Business Innovation Research (SBIR) program.